Asarfi Hospital Limited has announced its unaudited financial results for the half-year ended September 30, 2025, along with securing a significant loan for expansion. The company's Board of Directors approved the results at a meeting held on November 10, 2025.

Financial Results

The company has released both standalone and consolidated financial results for the half-year. The statutory auditors have issued an unmodified opinion on the financial statements, indicating compliance with applicable accounting standards.

Expansion and Financing

Asarfi Hospital has secured financing from the State Bank of India (SBI) to support its growth initiatives:

The total financing package amounts to ₹6.68 crore, which is expected to enhance the hospital's capabilities and service offerings.

Corporate Structure

Asarfi Hospital Limited operates primarily in the hospital segment. The company has a subsidiary named Asarfi Educational Foundation.

Regulatory Compliance

The financial results were reviewed by the Audit Committee and subsequently approved by the Board of Directors. The company has complied with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Market Implications

The addition of a new Cath Lab at the Dhanbad facility suggests that Asarfi Hospital is investing in advanced medical technologies. This expansion could potentially enhance the hospital's cardiac care capabilities.

The bank guarantee for empanelments with corporates and PSUs indicates that the hospital is seeking to broaden its patient base through strategic partnerships.

The company's shares are listed on the BSE SME platform, which exempts it from the mandatory adoption of IND AS (Indian Accounting Standards) as per MCA notification dated February 16, 2015.

Asarfi Hospital Limited , a leading healthcare provider in Eastern India, has reported robust financial results for the second quarter and half-year ended September 30, 2025, alongside securing significant funding for expansion.

Financial Highlights

The company's standalone financial results show impressive growth:

The consolidated results mirror this strong performance, with revenue reaching ₹80.57 crore for H1 FY2026, marking a 50% year-on-year increase.

Operational Performance

Asarfi Hospital has shown significant improvement in key operational metrics:

Super-Specialty Hospital Unit

• ARPOB (Average Revenue Per Occupied Bed) increased to ₹19,839 in H1 FY2026 from ₹16,925 in H1 FY2025
• Bed occupancy rate improved to 64% from 59% year-on-year

Cancer Hospital Unit

• ARPOB saw a substantial rise to ₹41,401 in H1 FY2026 from ₹16,602 in H1 FY2025
• Occupancy rate increased to 44% from 26% year-on-year

Expansion and Funding

During the quarter, Asarfi Hospital secured important funding for its growth initiatives:

1. A term loan of ₹4.68 crore from State Bank of India for purchasing and installing a new Cath Lab at their Dhanbad facility
2. A ₹2.00 crore fund-based Bank Guarantee limit for corporate and PSU empanelments

These financial arrangements are expected to enhance the hospital's capabilities and market position.

Strategic Developments

The company has entered into a partnership with Gleneagles Chennai to establish Jharkhand's first-ever Multi-Organ Transplant Unit. This collaboration aims to provide world-class transplant services for heart, lungs, kidney, liver, and bone marrow under one roof, potentially transforming Jharkhand from a "Medical Desert" into a "Medical Destination."

Future Outlook

Asarfi Hospital's Vision 2027 includes ambitious targets:

• Expanding to 500 beds
• Achieving ₹200 crore in revenues
• Maintaining EBITDA margins of 25-27%
• Targeting PAT margins of 13-15%

The company plans to increase bed capacity in its super-specialty hospital from 265 to 350 and in the cancer hospital from 65 to 150 within the next two years.

With its strong financial performance, strategic expansions, and partnerships, Asarfi Hospital Limited appears well-positioned for continued growth in the healthcare sector of Eastern India.